One targets telomeres. One targets mitochondria. They're not competing — they address different hallmarks of aging. Here's how to think about both.
Research context only. All content is educational based on published research. Not medical advice.
Epithalon and NAD+ work on different biological processes — both are considered hallmarks of aging, but they're not the same problem or the same solution. Understanding the distinction helps frame what each compound actually does.
| Epithalon | NAD+ / Precursors | |
|---|---|---|
| Primary target | Telomere length / pineal function | NAD+ levels / mitochondrial function |
| Key mechanism | Telomerase activation | Sirtuin activation, PARP repair, energy metabolism |
| Form | Injectable peptide | Oral supplement (NMN, NR) or IV/SubQ NAD+ |
| Dosing schedule | Short cycles 2x/year | Daily continuous supplementation |
| Evidence base | Russian clinical data (40+ yrs) | Western preclinical + growing human trials |
| Cost per cycle | Moderate (short cycles) | Variable (oral supplements cheap; IV NAD+ expensive) |
| Hallmark addressed | Telomere attrition | Mitochondrial dysfunction, epigenetic alterations |
The hallmarks of aging framework (Lopez-Otin et al.) describes multiple distinct biological processes that drive aging: telomere attrition, genomic instability, epigenetic alterations, mitochondrial dysfunction, cellular senescence, and others. No single compound addresses all of them.
Epithalon specifically targets telomere attrition — the gradual shortening of chromosomal caps that limits how many times cells can divide. It also addresses circadian disruption (via pineal/melatonin) and oxidative stress.
NAD+ targets mitochondrial dysfunction and energy metabolism. NAD+ declines ~50% between age 20 and 60. Its reduction impairs sirtuin activity (epigenetic regulation), PARP-mediated DNA repair, and cellular energy production.
The stack rationale: Because they address different hallmarks, using both simultaneously covers more of the aging biology than either alone. Epithalon handles telomeres and pineal; NAD+ handles mitochondria and sirtuins. Most serious longevity researchers use multiple approaches across different hallmarks — not just one.
Honest note: Longevity research is still developing rapidly. Neither compound has the kind of large-scale Phase 3 human data that would let us confidently quantify lifespan extension in humans. Both have meaningful mechanistic and preclinical evidence. Stack them as research tools with appropriate epistemic humility about the human outcome data.
COA-verified vendor pricing with promo codes and reconstitution guide.
View Pricing → Dosage CalculatorCOA-verified vendor pricing with promo codes and reconstitution guide.
View Pricing → Dosage Calculator